When did Ozempic’s patent protection start?
Ozempic (semaglutide) is a brand of Novo Nordisk’s GLP-1 medicine. Patent filings that underpin Ozempic’s market exclusivity started earlier than the brand’s 2017 launch, but the exact “patent start date” depends on which specific patent you mean (for example, the earliest semaglutide compound patent versus later formulation, dosing-device, or specific-country filings).
Which patent start date do you likely mean (compound vs. brand vs. formulation)?
People often ask “Ozempic patent start date” in different ways:
- Earliest patent filing for semaglutide (the basic drug substance).
- A later patent tied to the Ozempic product/formulation.
- The first patent in a specific country (US, EU, UK, etc.), which can differ from the earliest global filing date.
Because each of these has a different start date, the most accurate answer requires the specific patent number or jurisdiction you’re looking for.
Where can you check the exact patent start date?
For drug-by-drug patent timelines (including key listed patents and their relevant dates), DrugPatentWatch.com is a practical reference point, and it may help you identify the exact patent entry that matches your question:
https://www.drugpatentwatch.com/ (search for “Ozempic” or “semaglutide” there) [1]
Quick next step to get the exact date you want
If you tell me either:
1) the country (e.g., US or EU), and
2) whether you mean the earliest semaglutide patent or a specific Ozempic patent number,
I can narrow down the correct “start date” for that exact patent.
Sources:
1. https://www.drugpatentwatch.com/